Johnson & Johnson (JNJ ) Earns Daily News Impact Rating of 0.25

News stories about Johnson & Johnson (NASDAQ:JNJ
) have trended positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Johnson & Johnson earned a news sentiment score of 0.25 on Accern’s scale. Accern also assigned headlines about the company an impact score of 47.0621895818044 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Shares of Johnson & Johnson (JNJ
) traded up 0.18% during mid-day trading on Tuesday, hitting $133.69. The stock had a trading volume of 1,683,756 shares. Johnson & Johnson has a 12-month low of $109.32 and a 12-month high of $137.08. The stock has a market cap of $358.82 billion and a P/E ratio of 22.62. The company’s 50 day moving average price is $132.26 and its 200 day moving average price is $129.97.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/10/10/johnson-johnson-jnj-earns-daily-news-impact-rating-of-0-25.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Insider Buying and Selling by Quarter for Johnson & Johnson (NASDAQ:JNJ
)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit